CG Oncology (CGON) Non-Current Deferred Tax Liability (2025)

CG Oncology (CGON) reported Non-Current Deferred Tax Liability of $30000.0 for Q4 2025.

CG Oncology (CGON) Non-Current Deferred Tax Liability (2025) Analysis & Trends

CG Oncology has reported Non-Current Deferred Tax Liability for 1 years, with the latest figure at $30000.0 in Q4 2025.

For the quarter ending Q4 2025, Non-Current Deferred Tax Liability changed N/A year-over-year to $30000.0; the trailing twelve-month figure through Dec 2025 stood at $30000.0 (changed N/A YoY), and the FY2025 full-year result was $30000.0, changed N/A from the prior year.
Non-Current Deferred Tax Liability for Q4 2025 stood at $30000.0.
The five-year high for Non-Current Deferred Tax Liability was $30000.0 in Q4 2025, with the low at $30000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn
9	Abivax	90.15 Bn	90.15 Bn	-
10	CG Oncology	5.04 Bn	5.04 Bn	-1.88 Mn

Download Data

Date	Value
Dec 31, 2025	30,000.00
Dec 31, 2025	30,000.00